PL1636593T3 - Modulowanie oddziaływania pomiędzy łańcuchem beta HGF i c-met. - Google Patents

Modulowanie oddziaływania pomiędzy łańcuchem beta HGF i c-met.

Info

Publication number
PL1636593T3
PL1636593T3 PL04754499T PL04754499T PL1636593T3 PL 1636593 T3 PL1636593 T3 PL 1636593T3 PL 04754499 T PL04754499 T PL 04754499T PL 04754499 T PL04754499 T PL 04754499T PL 1636593 T3 PL1636593 T3 PL 1636593T3
Authority
PL
Poland
Prior art keywords
met
modulating
interaction
beta chain
hgf
Prior art date
Application number
PL04754499T
Other languages
English (en)
Inventor
Daniel K Kirchhofer
Robert A Lazarus
Xiaoyi Yao
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33555430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1636593(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PL1636593T3 publication Critical patent/PL1636593T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL04754499T 2003-06-06 2004-06-04 Modulowanie oddziaływania pomiędzy łańcuchem beta HGF i c-met. PL1636593T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US47677803P 2003-06-06 2003-06-06
US53211703P 2003-12-23 2003-12-23
PCT/US2004/017901 WO2005001486A1 (en) 2003-06-06 2004-06-04 Modulating the interaction between hgf beta chain and c-met
EP04754499A EP1636593B9 (en) 2003-06-06 2004-06-04 Modulating the interaction between hgf beta chain and c-met

Publications (1)

Publication Number Publication Date
PL1636593T3 true PL1636593T3 (pl) 2009-08-31

Family

ID=33555430

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04754499T PL1636593T3 (pl) 2003-06-06 2004-06-04 Modulowanie oddziaływania pomiędzy łańcuchem beta HGF i c-met.

Country Status (17)

Country Link
US (8) US20060035278A9 (pl)
EP (3) EP2093570A1 (pl)
JP (1) JP2007526447A (pl)
KR (2) KR20110117728A (pl)
AT (1) ATE425463T1 (pl)
AU (1) AU2004252475A1 (pl)
CA (1) CA2528343A1 (pl)
DE (1) DE602004019919D1 (pl)
DK (1) DK1636593T5 (pl)
ES (1) ES2323425T3 (pl)
HK (1) HK1092872A1 (pl)
HR (1) HRP20090324T1 (pl)
MX (1) MXPA05013181A (pl)
PL (1) PL1636593T3 (pl)
PT (1) PT1636593E (pl)
SI (1) SI1636593T1 (pl)
WO (1) WO2005001486A1 (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
CN103880955A (zh) * 2003-07-18 2014-06-25 安姆根有限公司 肝细胞生长因子的特异性结合物
EP1810037B1 (en) 2004-10-20 2010-07-21 PEAS Institut AB Assessment of biological activity of hepatocyte growth factor (hgf)
PL1846406T3 (pl) 2005-02-09 2011-04-29 Arqule Inc Pochodne imidowe kwasu maleinowego, kompozycje farmaceutyczne i sposoby leczenia nowotworów
WO2006104912A2 (en) * 2005-03-25 2006-10-05 Genentech, Inc. C-met mutations in lung cancer
US7615529B2 (en) * 2005-03-25 2009-11-10 Genentech, Inc. Methods and compositions for modulating hyperstabilized c-met
JP5222720B2 (ja) 2005-04-15 2013-06-26 ジェネンテック， インコーポレイテッド ＨＧＦβ鎖変異体
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
CA2655128A1 (en) * 2006-06-08 2007-12-21 Array Biopharma Inc. Quinoline compounds and methods of use
ES2582656T3 (es) 2006-12-19 2016-09-14 Genentech, Inc. Antagonistas específicos del VEGF para terapia adyuvante y neoadyuvante, y el tratamiento de tumores en fase temprana
BRPI0813355A2 (pt) 2007-06-22 2014-12-30 Arqule Inc Compostos de quinazolinona e métodos de uso dos mesmos
CN101801961B (zh) 2007-06-22 2014-09-24 艾科尔公司 吡咯烷酮、吡咯烷-2,5-二酮、吡咯烷和硫代琥珀酰亚胺衍生物、组合物以及治疗癌症的方法
JP5490688B2 (ja) 2007-06-22 2014-05-14 アークル インコーポレイテッド 癌の治療のためのインドリルピロリジン
WO2009062143A2 (en) * 2007-11-09 2009-05-14 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium using cytokines and variants thereof
CN102014913A (zh) * 2008-03-06 2011-04-13 健泰科生物技术公司 C-met和egfr拮抗剂的联合疗法
US9157920B2 (en) * 2009-06-26 2015-10-13 Peas Institut Ab Method for determining biologically active HGF
CA2778481A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Anti-hepsin antibodies and methods using same
EP2545077B1 (en) 2010-03-10 2018-10-31 Genmab A/S Monoclonal antibodies against c-met
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
CN102643268B (zh) 2011-12-30 2014-05-21 沈阳药科大学 喹啉类及噌啉类化合物及其应用
WO2013143376A1 (zh) 2012-03-26 2013-10-03 武汉盛云生物医药科技有限责任公司 含1，2，4-三嗪-3，5-二酮的喹啉类化合物及其应用
ME03486B (me) 2012-10-12 2020-01-20 Medimmune Ltd Pirolobenzodiazepini i njihovi konjugati
CN105209077B (zh) 2013-03-13 2019-06-11 麦迪穆有限责任公司 吡咯并苯并二氮杂卓以及其结合物
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
CN107002119A (zh) 2014-03-24 2017-08-01 豪夫迈·罗氏有限公司 使用c‑met拮抗剂的癌症治疗及前者与hgf表达的关联
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US20180057595A1 (en) 2015-03-16 2018-03-01 Celldex Therapeutics, Inc. Anti-MET Antibodies and Methods of Use Thereof
JP2019534882A (ja) 2016-10-11 2019-12-05 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ 免疫介在性療法薬を有する抗体−薬物コンジュゲート
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
MX2020012418A (es) 2018-05-23 2021-04-28 Adc Therapeutics Sa Adyuvante molecular.
JP7380999B2 (ja) * 2018-09-06 2023-11-15 国立大学法人 東京大学 環状ペプチド
CN114340684A (zh) 2019-09-16 2022-04-12 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
JP2755395B2 (ja) 1987-09-23 1998-05-20 ブリストル―マイアーズ スクイブ コムパニー Ｈｉｖ感染細胞に殺作用する抗体異種結合体
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DK0479909T3 (da) 1989-06-29 1997-04-07 Medarex Inc Bispecifikke reagenser til AIDS-behandling
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6344321B1 (en) * 1990-06-11 2002-02-05 Gilead Sciences, Inc. Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5780279A (en) 1990-12-03 1998-07-14 Genentech, Inc. Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
EP0520158A1 (en) * 1991-05-10 1992-12-30 PHARMACIA S.p.A. Truncated forms of the hepatocyte growth factor (HGF) receptor
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5328837A (en) * 1992-05-18 1994-07-12 Genentech, Inc. Hepatocyte growth factor protease domain variants
ATE196606T1 (de) 1992-11-13 2000-10-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma
ES2151541T3 (es) 1992-12-02 2001-01-01 Alkermes Inc Microesferas que contienen hormona del crecimiento de liberacion prolongada.
BR9509201A (pt) 1994-09-09 1997-12-30 Takeda Chemical Industries Ltd Preparação de liberação sustemtada uso de um sal de metal polivalente insolúvel em água ou ligeiramente solúvel em água e processo para produzir uma preparação de liberação sustentada
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5647409A (en) 1995-04-04 1997-07-15 Allergan On-site syringe filling apparatus for viscoelastic materials, and corresponding method for on-site syringe filling
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
PT831787E (pt) 1995-06-07 2002-02-28 Alkermes Inc Composicao para libertacao sustentada da hormona de crescimento humano
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US5911252A (en) 1997-04-29 1999-06-15 Cassel; Douglas Automated syringe filling system for radiographic contrast agents and other injectable substances
US6677377B2 (en) * 2000-06-21 2004-01-13 Georgetown University School Of Medicine Structure based discovery of inhibitors of matriptase for the treatment of cancer and other conditions

Also Published As

Publication number Publication date
PT1636593E (pt) 2009-06-03
DE602004019919D1 (de) 2009-04-23
US20170106042A1 (en) 2017-04-20
KR20060017634A (ko) 2006-02-24
WO2005001486A1 (en) 2005-01-06
HRP20090324T1 (hr) 2010-02-28
MXPA05013181A (es) 2006-06-23
EP1636593B1 (en) 2009-03-11
US20100040634A1 (en) 2010-02-18
EP2367008A3 (en) 2014-12-24
ES2323425T3 (es) 2009-07-15
EP1636593A1 (en) 2006-03-22
US20110177058A1 (en) 2011-07-21
HK1092872A1 (en) 2007-02-16
EP1636593B9 (en) 2009-12-16
US20150126448A1 (en) 2015-05-07
SI1636593T1 (sl) 2009-08-31
DK1636593T5 (da) 2009-07-27
ATE425463T1 (de) 2009-03-15
EP2367008A2 (en) 2011-09-21
US20070129301A1 (en) 2007-06-07
KR20110117728A (ko) 2011-10-27
JP2007526447A (ja) 2007-09-13
US20190054138A1 (en) 2019-02-21
US20130143813A1 (en) 2013-06-06
US20050037431A1 (en) 2005-02-17
US20060035278A9 (en) 2006-02-16
AU2004252475A1 (en) 2005-01-06
DK1636593T3 (da) 2009-06-15
EP2093570A1 (en) 2009-08-26
KR101148657B1 (ko) 2012-07-05
CA2528343A1 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
HK1092872A1 (en) Modulating the interaction between hgf beta chain and c-met
NO20075412L (no) Fremgangsmater og preparater til modulering av hyperstabilisert C-MET
DK1644336T3 (da) Nitrogenholdige heteroarylforbindelser og deres anvendelse til forøgelse af endogent erythropoietin
BR0003184A (pt) Métodos para tratamento de pigmentação da pele
WO2003068944A3 (en) METHODS AND COMPOSITION FOR MODULATING TYPE I MUSCLE FORMATION USING PGC-1α-
HK1097412A1 (en) Nucleating agents
AU2003274652A8 (en) Compounds, compositions and methods for modulating fat metabolism
IL175885A0 (en) Monovalent antibody fragments useful as therapeutics
DE602004010791D1 (de) 2,5-substituiertetetrahydroisochinoline zur verwendung als 5-ht6 modulatoren
DK1434791T3 (da) Specifikke bindingsmidler til human angiopoietin-2
ZA200705177B (en) Lyophilization of virosomes
TNSN07222A1 (en) Nematicidal compositions
WO2005107461A3 (en) Modulating lymphatic function
NO20062062L (no) Procsesser for preparering av forskjellige former for (S)-(+)-clopidogrel bisulfat
AU2002352832A1 (en) 3-alkylated-5,5',6,6',7,7',8,8'-octahydro-2,2'-binaphthols and 3,3'-dialkylated-5,5',6,6',7,7',8,8'-octahydro-2,2'-binaphthols and processes for making them
DK1121388T3 (da) Polyamidsammensætninger stabiliseret med kobberkomplekser og organiske halogenforbindelser
DK1560812T3 (da) Aminocyclohexyletherforbindelser og anvendelser deraf
ATE342105T1 (de) Stabilisiertes antitranspirantmittel sojaprodukte enthaltend
SI1373503T1 (sl) Nevtroficni dejavniki
MXPA05013251A (es) Composiciones para estado de oxigeno mejorado en animales de compania.
HK1083202A1 (en) Anti-infarction molecules
IL177555A0 (en) Methods for treating resistant or refractory tumors
ATE400273T1 (de) 1-2'-(1,4'-biperidin-1'-yl)-1-(phenyl)- ethylcyclohexanol-derivate als monoamin- wiederaufnahme-modulatoren zur behandlung von vasomotorischen symptomen
BRPI0411639A (pt) uso de compostos de ferro e zinco biodisponìveis e pelo menos uma vitamina b e método para auxiliar o desenvolvimento de cognitivo ou o desempenho cognitivo
PL1776103T3 (pl) Kompleksy rutenu do leczenia raków